Skip to main content
. Author manuscript; available in PMC: 2017 Feb 17.
Published in final edited form as: Radiother Oncol. 2016 Feb 17;118(2):304–314. doi: 10.1016/j.radonc.2016.01.019

Table 1.

Demographic and clinical data of study patient population.

All patients (n=300) Asymptomatic Swallowing (n=266) Chronic-RAD (n=34)

T-category n. Percent n. Percent n. Percent
1 53 17.67% 51 19.17% 2 5.88%
2 139 46.33% 128 48.12% 11 32.35%
3 68 22.67% 60 22.56% 8 23.53%
4 40 13.33% 27 10.15% 13 38.24%
N-category
0 16 5.33% 14 5.26% 2 5.88%
1 12 4.00% 12 4.51% 0 0.00%
2a 21 7.00% 21 7.89% 0 0.00%
2b 167 55.67% 150 56.39% 17 50.00%
2c 71 23.67% 57 21.43% 14 41.18%
3 13 4.33% 12 4.51% 1 2.94%
Site
Base of tongue 164 54.67% 144 54.14% 20 58.82%
Tonsil 131 43.67% 118 44.36% 15 44.12%
Other 5 1.67% 4 1.50% 1 2.94%
Smoking status
Never 55 18.33% 46 17.29% 9 26.47%
<10 pack-years 109 36.33% 99 37.22% 10 29.41%
>10 pack-years 136 45.33% 121 45.49% 15 44.12%
Sex
Male 272 90.67% 238 89.47% 34 100.00%
Female 28 9.33% 28 10.53% 0 0.00%
Ethnicity
White 283 94.33% 251 94.36% 32 94.12%
Black 7 2.33% 6 2.26% 1 2.94%
Hispanic 9 3.00% 8 3.01% 1 2.94%
Asian/Pacific Islander 1 0.33% 1 0.38% 0 0.00%
Chemotherapy
Cisplatin 195 65.00% 99 37.22% 6 17.65%
Cetuximab 105 35.00% 167 62.78% 28 82.35%
IMRT technique
Split-field 284 94.6% 253 95% 31 91%
Whole-field 16 5.4% 13 5% 3 9%
IMRT fractionation
Once-daily 262 87% 233 87.5% 29 85%
Accelerated 38 13% 33 12.5% 5 15%
Mean±SD Median (Range) Mean±SD Median (Range) Mean±SD Median (Range)
Age (years) 56±9 56 (28–81) 56±8 55 (36–81) 59±10 59 (28–81)
RT dose (Gy) 69±2 70 (64–75) 68±2 70 (64–75) 70±1 70 (66–72)
RT fractions delivered 33±2 33 (29–35) 33±2 33 (29–35) 33±2 33 (30–35)